In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fisher Scientific buys Apogent for $3.7bn

Executive Summary

Continuing on its buying spree, life sciences company Fisher Scientific has paid $3.7bn ($2.7bn in stock plus the assumption of debt) to buy Apogent Technologies (develops laboratory and life science research equipment). The deal values Apogent at $30.15 a share, a slight premium to its pre-announcement market average.
Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies